Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alclometasone dipropionate · 1 trial · 4 indications
Incorrect duration of use was defined as the use of study medication for more than 7 consecutive days and/or more than three times in a day. Participants were asked the reasons of doing so and they were allowed to select multiple reasons also, if applicable.
| Arm | Type | Description |
|---|---|---|
| Alclometasone dipropionate cream | EXPERIMENTAL | Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days. |
| Name | Type | Description |
|---|---|---|
| Alclometasone dipropionate cream | DRUG | Alclometasone dipropionate cream 0.05% (15 g) |
Inclusion Criteria: * Age: At least 12 years of age. * Condition: Currently experiencing itch associated with one of the following skin conditions: * psoriasis or eczema, * minor skin conditions such as those caused by poison ivy, oak, or sumac, insect bites, or use of cosmetics, soaps, deterg...
Alclometasone dipropionate is a small molecule being studied for the treatment of eczema. It is an investigational drug in Phase 2 clinical development, and it has also been evaluated in conditions such as allergy symptoms, psoriasis, and itch. It is not yet approved for any use.
Alclometasone dipropionate is being developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical research on this drug for eczema and related skin conditions.
Alclometasone dipropionate is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in active trials.
Alclometasone dipropionate has one completed clinical trial, NCT02075632, titled 'Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream.' This Phase 2 study enrolled 310 participants aged 12 years and older with eczema, allergy symptoms, psoriasis, and itch.
Alclometasone dipropionate is a distinct drug entity. No alternative names have been reported for this compound in the available clinical data, so it is not known to be the same as any other marketed or investigational drug.